:: CLDF ::

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Hepatol Int.?2025 Feb 27.?doi: 10.1007/s12072-024-10774-3.?Online ahead of print.

Mohammed Eslam?1,?Jian-Gao Fan?2,?Ming-Lung Yu?3,?Vincent Wai-Sun Wong?4,?Ian Homer Cua?5,?Chun-Jen Liu?6,?Tawesak Tanwandee?7,?Rino Gani?8,?Wai-Kay Seto?9?10,?Shahinul Alam?11,?Dan Yock Young?12,?Saeed Hamid?13,?Ming-Hua Zheng?14,?Takumi Kawaguchi?15,?Wah-Kheong Chan?16,?Diana Payawal?17,?Soek-Siam Tan?18,?George Boon-Bee Goh?19?20,?Simone I Strasser?21,?Hang Dao Viet?22,?Jia-Horng Kao?23,?Won Kim?24,?Seung Up Kim?25,?Shelley E Keating?26,?Yusuf Yilmaz?27,?Lubna Kamani?28,?Chia-Chi Wang?29,?Yasser Fouad?30,?Zaigham Abbas?31,?Sombat Treeprasertsuk?32,?Kessarin Thanapirom?32,?Mamun Al Mahtab?33,?Undram Lkhagvaa?34,?Oidov Baatarkhuu?35,?Ashok Kumar Choudhury?36,?Catherine A M Stedman?37,?Abhijit Chowdhury?38,?A Kadir Dokmeci?39,?Fu-Sheng Wang?40,?Han-Chieh Lin?41,?Jee-Fu Huang?42,?Jess Howell?43?44?45?46,?Jidong Jia?47,?Mohamed Alboraie?48,?Stuart K Roberts?49,?Masato Yoneda?50,?Hasmik Ghazinian?51,?Aram Mirijanyan?51,?Yuemin Nan?52,?Cosmas Rinaldi Adithya Lesmana?53,?Leon A Adams?54,?Gamal Shiha?55,?Manoj Kumar?56,?Necati Örmeci?57,?Lai Wei?58,?George Lau?59?60,?Masao Omata?61?62,?Shiv K Sarin?63,?Jacob George?64

The Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B

Liver Int.?2025 Mar;45(3):e70042.?doi: 10.1111/liv.70042.

Lesley A Patmore?1,?Kirsi van Eekhout?2,?Özgür M Koc?3,?Robert J de Knegt?1,?Harry L A Janssen?1?4,?Willem P Brouwer?1,?Matthijs Kramer?3?5,?Pieter Honkoop?6,?Joep de Bruijne?7,?Greet J Boland?8,?Douwe F Postma?9,?Hans Blokzijl?10,?Robert A de Man?1,?R Bart Takkenberg?2,?Milan J Sonneveld?1

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis

Curr Diab Rep.?2025 Feb 18;25(1):23.?doi: 10.1007/s11892-025-01579-1.

Marina W Takawy?1,?Manal F Abdelmalek?2

Impact of Helicobacter pylori Eradication on Clinical and Laboratory Parameters in Non-alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Curr Med Sci.?2025 Feb 25.?doi: 10.1007/s11596-025-00001-x.?Online ahead of print.

Fouad Jaber?1,?Saqr Alsakarneh?2,?Azizullah Beran?3,?Tala Alsharaeh?4,?Ahmed-Jordan Salahat?4,?Abdelrahman Abdelshafi?5,?Islam Mohamed?6,?Willie Johnson?7,?Khaled Elfert?8,?Mohammad Jaber?9,?Mohammad Almeqdadi?10,?Mohamed Ahmed?11,?Hassan Ghoz?12,?Wendell K Clarkston?11?13,?John H Helzberg?11?13

The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists

Expert Opin Investig Drugs.?2025 Feb 27.?doi: 10.1080/13543784.2025.2473062.Online ahead of print.

Naim Alkhouri?1,?Michael Charlton?2,?Meagan Gray?3,?Mazen Noureddin?4

Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis

J Clin Exp Hepatol.?2025 Mar-Apr;15(2):102427.?doi: 10.1016/j.jceh.2024.102427.Epub 2024 Oct 16.

Katherine M Cooper?1,?Ami K Patel?1,?Christopher A Zammitti?1,?Ellen Murchie?1,?Alessandro Colletta?1?2,?Deepika Devuni?1?2

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)

JHEP Rep.?2024 Nov 16;7(3):101276.?doi: 10.1016/j.jhepr.2024.101276.?eCollection 2025 Mar.

Zobair M Younossi?1,?Maria Stepanova?1,?Issah Younossi?1,?Andrei Racila?1

How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease

Acta Pharmacol Sin.?2025 Mar;46(3):515-524.?doi: 10.1038/s41401-024-01396-4.Epub 2024 Nov 7.

Brian E Harvey?1

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

Aliment Pharmacol Ther.?2025 Feb 18.?doi: 10.1111/apt.70020.?Online ahead of print.

Zobair M Younossi?1?2,?Homie Razavi?3,?Michael Sherman?4?5,?Alina M Allen?6,?Quentin M Anstee?7?8,?Kenneth Cusi?9,?Scott L Friedman?10,?Eric Lawitz?11,?Jeffrey V Lazarus?12?13?14,?Detlef Schuppan?15?16,?Manuel Romero-Gómez?17,?Jörn M Schattenberg?18,?Miriam B Vos?19,?Vincent Wai-Sun Wong?20,?Vlad Ratziu?21,?Marcus Hompesch?22,?Arun J Sanyal?23,?Rohit Loomba?24

10.

Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuO

Liver Int.?2025 Mar;45(3):e70036.?doi: 10.1111/liv.70036.

Stephen A Harrison?1,?Patrick Mayo?2,?Todd Hobbs?2,?Caroline Zhao?2,?Carlos Canizares?2,?Robert Foster?2,?Michael P McRae?3,?Steve M Helmke?4,?Gregory T Everson?4

11.

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH

J Hepatol.?2025 Feb 10:S0168-8278(25)00069-8.?doi: 10.1016/j.jhep.2025.01.032.Online ahead of print.

Stephen A Harrison?1,?Naim Alkhouri?2,?Grisell Ortiz-Lasanta?3,?Madhavi Rudraraju?4,?Dean Tai?5,?Katy Wack?6,?Amrik Shah?7,?Robin Besuyen?8,?Hilde H Steineger?8,?David A Fraser?9,?Arun J Sanyal?10;?ICONA Study Investigators

12.

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021

JHEP Rep.?2024 Nov 14;7(3):101271.?doi: 10.1016/j.jhepr.2024.101271.?eCollection 2025 Mar.

Gong Feng?1?2,?Giovanni Targher?3?4,?Christopher D Byrne?5,?Yusuf Yilmaz?6?7,?Vincent Wai-Sun Wong?8,?Cosmas Rinaldi Adithya Lesmana?9?10?11,?Leon A Adams?12?13,?Jerome Boursier?14?15,?George Papatheodoridis?16,?Mohamed El-Kassas?17?18,?Nahum Méndez-Sánchez?19?20,?Silvia Sookoian?21?22?23,?Laurent Castera?24,?Wah-Kheong Chan?25,?Feng Ye?2,?Sombat Treeprasertsuk?26,?Helena Cortez-Pinto?27,?Hon Ho Yu?28,?Won Kim?29?30,?Manuel Romero-Gómez?31,?Atsushi Nakajima?32,?Khin Maung Win?33,?Seung Up Kim?34,?Adriaan G Holleboom?35,?Giada Sebastiani?36,?Ponsiano Ocama?37,?John D Ryan?38,?Monica Lup?or-Platon?39,?Hasmik Ghazinyan?40,?Mamun Al-Mahtab?41,?Saeed Hamid?42,?Nilanka Perera?43,?Khalid A Alswat?44,?Qiuwei Pan?45,?Michelle T Long?46,?Vasily Isakov?47,?Man Mi?1,?Marco Arrese?48,?Arun J Sanyal?49,?Shiv Kumar Sarin?50,?Nathalie Carvalho Leite?51,?Luca Valenti?52?53,?Philip N Newsome?54,?Hannes Hagström?55?56,?Salvatore Petta?57,?Hannele Yki-Järvinen?58?59,?Jörn M Schattenberg?60,?Marlen I Castellanos Fernández?61,?Isabelle A Leclercq?62,?Gulnara Aghayeva?63,?Abdel-Naser Elzouki?64?65?66,?Ali Tumi?67,?Ala I Sharara?68,?Asma Labidi?69,?Faisal M Sanai?70,?Khaled Matar?71,?Maen Al-Mattooq?72,?Maisam Waid Akroush?73,?Mustapha Benazzouz?74,?Nabil Debzi?75,?Maryam Alkhatry?76,?Salma Barakat?77,?Said A Al-Busafi?78,?John Rwegasha?79,?Wah Yang?80,?Agyei Adwoa?81?82,?Christopher Kenneth Opio?83,?Mohammadjavad Sotoudeheian?84?85,?Yu Jun Wong?86?87,?Jacob George?88,?Ming-Hua Zheng?89?90

13.

Food Insecurity Is Increasing and Is More Common Among Persons with Chronic Liver Disease

Dig Dis Sci.?2025 Feb 21.?doi: 10.1007/s10620-025-08928-w.?Online ahead of print.

Cindy W Leung?1,?Elliot B Tapper?2

14.

Multi-Modal Diagnostic Imaging of Metabolic Dysfunction-Associated Steatotic Liver Disease: Non-invasive Analyses by Photoacoustic Ultrasound and MRI

Am J Pathol.?2025 Feb 13:S0002-9440(25)00048-3.?doi: 10.1016/j.ajpath.2025.01.012.Online ahead of print.

Alissa Keegan?1,?Gayathri Malamal?2,?Yichien Lee?1,?Kyle Korolowicz?1,?Blythe D Shepard?3,?Carolyn M Ecelbarger?4,?Mariana Moya Rubiano?1,?Maria Laura Avantaggiati?1,?Moshe Levi?5,?Laurie Rich?2,?Massimo Alfano?6,?Avi Rosenberg?7,?Stanley Fricke?8,?Chris Albanese?9,?Jithin Jose?10,?Olga Rodriguez?11

15.

An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review

Diabetes Obes Metab.?2025 Mar;27(3):1113-1122.?doi: 10.1111/dom.16110.Epub 2024 Dec 9.

Jimmy Wen?1,?Adam Razick?2,?Christiane How-Volkman?1,?Ethan Bernstein?1,?Denise Nadora?1,?Alina Truong?1,?Daniel Razick?1,?Muzammil Akhtar?1,?Muhammad Karabala?1,?Eldo Frezza?1

16.

NAFLD vs MASLD (metabolic dysfunction associated steatotic liver disease) - why the need for a change of nomenclature?

J Clin Endocrinol Metab.?2025 Feb 19:dgaf094.?doi: 10.1210/clinem/dgaf094.Online ahead of print.

Amalia Gastaldelli?1,?Philip N Newsome?2

17.

Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials

Aliment Pharmacol Ther.?2025 Jan 14.?doi: 10.1111/apt.18498.?Online ahead of print.

Matheus Souza?1,?Marcio J M Amaral?1,?Luan C V Lima?1,?Cristiane Alves Villela-Nogueira?1

18.

Diabetes Obes Metab.?2025 Feb;27(2):710-718.doi: 10.1111/dom.16065.?Epub 2024 Nov 28.

Matthew J Armstrong?1?2?3,?Takeshi Okanoue?4,?Mads Sundby Palle?5,?Anne-Sophie Sejling?5,?Mohamed Tawfik?5,?Michael Roden?6?7?8

19.

Do Patients With NASH-related Cirrhosis Have Better Overall Survival Compared With Other Etiologies of Cirrhosis? A Population-based Study

?Clin Gastroenterol.?2025 Feb 1;59(2):177-182.doi: 10.1097/MCG.0000000000001992.

Ritu R Singh?1?2,?Harishankar Gopakumar?1,?Sonu Dhillon?1

20.

Modulating the microbiome in chronic liver diseases - current evidence on the role of fecal microbiota transplantation

Expert Rev Gastroenterol Hepatol.?2025Jan16:112.doi:10.1080/17474124.2025.2450707.?Online ahead of print.

Srishti Saha?1,?Bernd Schnabl?1?2

21.

Modeling the Health and Economic Impact of Pharmacologic Therapies for MASLD in the United States

Hepatol.?2025 Jan 18:S0168-8278(25)00015-7.?doi: 10.1016/j.jhep.2025.01.009.Online ahead of print.

Carolyn Wallace?1,?Ivane Gamkrelidze?1,?Chris Estes?1,?Homie Razavi?2,?Arun J Sanyal?3

22.

Metabolic dysfunction-associated steatotic liver disease in children

Gut.?2025 Jan 23:gutjnl-2023-331090.?doi: 10.1136/gutjnl-2023-331090.Online ahead of print.

Nidhi P Goyal?1?2,?Stavra Xanthakos?3,?Jeffrey B Schwimmer?4?2

23.

Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

Curr Cardiol Rep.?2025 Jan 18;27(1):28.?doi: 10.1007/s11886-024-02185-5.

Johannes Bernhard?1,?Lukas Galli?1,?Walter S Speidl?1,?Konstantin A Krychtiuk?2

24.

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia

Aliment Pharmacol Ther.?2025 Feb;61(3):456-464.?doi: 10.1111/apt.18377.?Epub 2024 Nov 5.

Maral Amangurbanova?1,?Daniel Q Huang?1?2?3,?Nabil Noureddin?1,?Kaleb Tesfai?1,?Richelle Bettencourt?1,?Harris Siddiqi?1,?Scarlett J Lopez?1,?Vanessa Cervantes?1,?Egbert Madamba?1,?Rohit Loomba?1?4

25.

Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters

Microbiome.?2025 Jan 14;13(1):9.?doi: 10.1186/s40168-024-02004-7.

Katherine J P Schwenger?1,?Julia K Copeland?2,?Yasaman Ghorbani?1,?Lina Chen?3?4,?Elena M Comelli?5,?David S Guttman?2,?Sandra E Fischer?1?4,?Timothy D Jackson?6?7,?Allan Okrainec?6?7,?Johane P Allard?8?9?10

Subscribe